Combining immunotherapy, targeted therapy, and radiation for advanced mucosal melanoma
Part of Cancer clinical trials.
This trial tests a combination of carilizumab (an immunotherapy drug) and apatinib (a targeted therapy) with radiation therapy for people with advanced mucosal melanoma that has come back or spread. The goal is to see if this triple approach can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have mucosal melanoma that has returned, cannot be removed by surgery, or has spread to other parts of the body.
- You have not had any systemic (whole-body) cancer drug treatment for your advanced disease before.
- You have at least one tumor that can be measured on a CT or MRI scan (at least 1 cm in size or a lymph node at least 1.5 cm).
- You have at least one tumor that can receive radiation therapy.
- You are in good general health (ECOG performance status 0 or 1), meaning you can carry out daily activities without help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
This trial tests a new combination of drugs (iparomlimab, tuvoraleimab, bevacizumab, and chemotherapy) as a first or second treatment for advanced acral or mucosal melanoma. It aims to see if this mix can help shrink or control the cancer.
This trial tests if adding sintilimab (an immunotherapy) to chemotherapy after surgery can lower the chance of mucosal melanoma coming back. It is for people whose melanoma has been fully removed and whose tumor tests positive for PD-L1.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Mucosal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.